January 26, 2015 12:31 PM ET


Company Overview of Prexa Pharmaceuticals, Inc.

Company Overview

Prexa Pharmaceuticals, Inc., a biotechnology company, develops oral small molecule monoamine reuptake inhibitors that act potently at the dopamine transporter. It offers PRX-12251, a dopamine-preferring triple reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin transporters. The company also provides mono and dual reuptake inhibitors. Its products are used to treat central nervous system diseases and disorders, such as attention deficit hyperactivity disorder, depression, and Parkinson’s disease. The company was founded in 2006 and is based in Boston, Massachusetts.

184 High Street

Boston, MA 02110

United States

Founded in 2006



Key Executives for Prexa Pharmaceuticals, Inc.

Age: 63
Chief Operating Officer
Age: 65
Chief Medical Officer
Chief Technology Officer
Executive Director of Development
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Xantech Pharmaceuticals Inc. United States
D-finitive Technologies, Inc. United States
Gen-Probe Prodesse, Inc. United States
Cell Habitats, Inc. United States
Laser Isotope Enrichment Laboratory United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Prexa Pharmaceuticals, Inc., please visit www.prexainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.